𝔖 Bobbio Scriptorium
✦   LIBER   ✦

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings

✍ Scribed by Enrique M Ocio; María-Victoria Mateos; Patricia Maiso; Atanasio Pandiella; Jesús F San-Miguel

Book ID
117784879
Publisher
The Lancet
Year
2008
Tongue
English
Weight
531 KB
Volume
9
Category
Article
ISSN
1470-2045

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II clinical trial of arsenic triox
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma
✍ C.C. Hofmeister; B. Jansak; N. Denlinger; E.H. Kraut; D.M. Benson; S.S. Farag 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 90 KB

In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As 2 O 3 ) with DVd (Doxil TM , vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followe

A Phase I–II trial of polyethylene glyco
A Phase I–II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma
✍ Neeraj R. Agrawal; Ronald M. Bukowski; Lisa A. Rybicki; Joanne Kurtzberg; Lewis 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## BACKGROUND Multiple myeloma remains an incurable disease. New agents are needed to improve therapy for patients with this disease. Previous investigators evaluated in vitro sensitivity of myeloma cells to polyethylene glycol‐conjugated L‐asparaginase (PEG‐L‐asparaginase) using the h